Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Pulmocide Ltd.

Headquarters: London, United Kingdom
Year Founded: 2013
Status: Private

BioCentury | Jun 8, 2023
Management Tracks

New CFO, commercial officer at Pulmocide

Plus: Helmling named CBO at eTheRNA, and updates from EpimAb, Ring, Amarna, XNK and more
BioCentury | Dec 6, 2022
Data Byte

Pulmocide joins trio of start-ups with venture raises

Entact Bio, Vega mark debuts alongside $52M series C extension for U.K.’s Pulmocide
BioCentury | Sep 20, 2021
Finance

Closing Europe’s largest biotech fund at $630M, Jeito readies to build portfolio

French VC gearing up to build portfolio of European companies focused on severe diseases in small patient populations
BioCentury | Jun 11, 2021
Finance

Investment in Pulmocide pushes Jeito portfolio into the clinic and beyond cell and gene therapy

Firm leads $92M in U.K. respiratory play
BioCentury | Mar 25, 2017
Finance

Respiratory redux

Pulmocide management, investor experience attracted SR One to lead $30.4M round
BioCentury | Mar 23, 2017
Financial News

Pulmocide completes venture finacing

BioCentury | Mar 20, 2017
Financial News

Pulmocide raises $30.4M in series B round

BioCentury | Feb 20, 2014
Cover Story

Europe's upwelling

BioCentury | Nov 25, 2013
Company News

Pulmocide board of directors update

BioCentury | Nov 25, 2013
Financial News

Pulmocide completes venture financing

Items per page:
1 - 10 of 11